Matchpoint: the game is not over for blast-phase chronic myeloid leukaemia
Mené sur 17 patients atteints d'une leucémie myéloïde chronique en phase blastique (durée médiane de suivi : 41 mois), cet essai de phase I/II évalue la dose maximale tolérée du ponatinib en combinaison avec une chimiothérapie de type FLAG-IDA (fludarabine, cytarabine, facteur de stimulation des colonies de granulocytes et idarubicine)
In the era of tyrosine-kinase inhibitors (TKIs), chronic myeloid leukaemia is no longera deadly disease. However, a small proportion of patients still have a short lifeexpectancy. The SPIRIT study showed a 15-year relative survival of 96% (95% CI 92–99) in patients with chronicmyeloid leukaemia, and the CML IV study showed a 10-year relative survival of 92% (95% CI 89–95). Chronic myeloid leukaemiaprogression was recorded in 45 (5·7%) of 789 patients recruited in the SPIRIT trial,including 35 (4·4%) with blast phase. 25 (55%) of the 45 patients in accelerated phase or blast crisis died. Median survivalafter progression was 7·9 months in the CML IV trial. Conversely, little is known about the epidemiology of the patients who are newly diagnosed in blast phase
The Lancet Haematology , commentaire, 2020